open access

Vol 91, No 5 (2020)
Research paper
Published online: 2020-05-29
Get Citation

Nasal bone in screening for Trisomy 18 and 13 at 11–13 + 6 weeks of gestation — own experiences

Bartosz Czuba1, Marek Maczka2, Wojciech Cnota1, Agata Wloch1, Agnieszka Jagielska1, Anna Niesluchowska-Hoxha1, Dariusz Borowski3
DOI: 10.5603/GP.2020.0047
·
Pubmed: 32495931
·
Ginekol Pol 2020;91(5):256-261.
Affiliations
  1. Department of Obstetrics and Gynecology in Ruda Slaska, Medical University of Silesia, Ruda Slaska, Poland
  2. Center for Prenatal Diagnostic, Opole, Poland
  3. Faculty of Health Sciences, Department of Obstetrics, Nicolaus Copernicus University in Torun, Collegium Medicum, Bydgoszcz, Poland

open access

Vol 91, No 5 (2020)
ORIGINAL PAPERS Obstetrics
Published online: 2020-05-29

Abstract

Objectives: The objective of the paper is the suitability assessment of screening for Trisomy 18 and 13 on the basis of NT
measurement, FHR, double test and assessment of Nasal Bone.
Material and methods: The study was performed in 6,661 singleton pregnancies. In each fetus NT, FHR, DV-PIV were
examined. Double test from maternal blood was examined. These ultrasound and biochemical factors were in combined
screening investigated. Additional ultrasound marker — Nasal Bone was and its impact on Trisomies 18 and 13 screening
was examined.
Results: Two groups of patients were compared — with chromosomal normal and chromosomal abnormalities — Trisomy
18 and 13. Detection Rate of Trisomies 18 and 13 at the risk cutoff 1/300 using combined screening was 84.1% and FPR
was 7.1%. Detection Rates of examined chromosomal abnormalities using screening with additional marker — NB was
93.2% and False Positive Rate — 5.6%.
Conclusions: It should be noted that the qualitative analysis of the assessment of NB in the first trimester significantly
influences the improvement of screening values focusing on Trisomy 18 and 13 detection. In summary, our research indicates
a more effective type of Trisomy 13 and 18 screening using NT, double test, maternal age, CRL and FHR as well as
nasal bone presence and absence.

Abstract

Objectives: The objective of the paper is the suitability assessment of screening for Trisomy 18 and 13 on the basis of NT
measurement, FHR, double test and assessment of Nasal Bone.
Material and methods: The study was performed in 6,661 singleton pregnancies. In each fetus NT, FHR, DV-PIV were
examined. Double test from maternal blood was examined. These ultrasound and biochemical factors were in combined
screening investigated. Additional ultrasound marker — Nasal Bone was and its impact on Trisomies 18 and 13 screening
was examined.
Results: Two groups of patients were compared — with chromosomal normal and chromosomal abnormalities — Trisomy
18 and 13. Detection Rate of Trisomies 18 and 13 at the risk cutoff 1/300 using combined screening was 84.1% and FPR
was 7.1%. Detection Rates of examined chromosomal abnormalities using screening with additional marker — NB was
93.2% and False Positive Rate — 5.6%.
Conclusions: It should be noted that the qualitative analysis of the assessment of NB in the first trimester significantly
influences the improvement of screening values focusing on Trisomy 18 and 13 detection. In summary, our research indicates
a more effective type of Trisomy 13 and 18 screening using NT, double test, maternal age, CRL and FHR as well as
nasal bone presence and absence.

Get Citation

Keywords

combined test Trisomy 18 Trisomy 13; first trimester nuchal translucency thickness; Nasal Bone; Serum free β-hCG; Pregnancy-associated plasma protein A

About this article
Title

Nasal bone in screening for Trisomy 18 and 13 at 11–13 + 6 weeks of gestation — own experiences

Journal

Ginekologia Polska

Issue

Vol 91, No 5 (2020)

Article type

Research paper

Pages

256-261

Published online

2020-05-29

DOI

10.5603/GP.2020.0047

Pubmed

32495931

Bibliographic record

Ginekol Pol 2020;91(5):256-261.

Keywords

combined test Trisomy 18 Trisomy 13
first trimester nuchal translucency thickness
Nasal Bone
Serum free β-hCG
Pregnancy-associated plasma protein A

Authors

Bartosz Czuba
Marek Maczka
Wojciech Cnota
Agata Wloch
Agnieszka Jagielska
Anna Niesluchowska-Hoxha
Dariusz Borowski

References (17)
  1. Brown R. Trisomy 13: 13+ Syndrome (Patau Syndrome). Encyclopedia of Special Education. 2014.
  2. Ghaffari SR, Tahmasebpour AR, Jamal A, et al. First-trimester screening for chromosomal abnormalities by integrated application of nuchal translucency, nasal bone, tricuspid regurgitation and ductus venosus flow combined with maternal serum free β-hCG and PAPP-A: a 5-year prospective study. Ultrasound Obstet Gynecol. 2012; 39(5): 528–534.
  3. zespół z. Polish Gynecological Society – Ultrasound Section Guidelines on ultrasound screening in gynecology – 2015. Polish Gynaecology. 2015; 86(8): 635–639.
  4. Nicolaides K, Węgrzyn P. Nicolaides K, Węgrzyn P, Badanie ultrasonograficzne między 11+0-13+6 tygodniem ciąży, Fetal Medicine Foundation, London. ; 2004.
  5. Adiego B, Martinez-Ten P, Illescas T, et al. First-trimester assessment of nasal bone using retronasal triangle view: a prospective study. Ultrasound Obstet Gynecol. 2014; 43(3): 272–276.
  6. Kozlowski P, Knippel AJ, Froehlich S, et al. Additional performance of nasal bone in first trimester screening. Ultraschall Med. 2006; 27(4): 336–339.
  7. Cicero S, Longo D, Rembouskos G, et al. Absent nasal bone at 11-14 weeks of gestation and chromosomal defects. Ultrasound Obstet Gynecol. 2003; 22(1): 31–35.
  8. Karadzov-Orlic N, Egic A, Filimonovic D, et al. Screening for aneuploidies by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-13+6 gestational weeks. Srpski arhiv za celokupno lekarstvo. 2012; 140(9-10): 606–611.
  9. Springett AL, Morris JK. Antenatal detection of Edwards (Trisomy 18) and Patau (Trisomy 13) syndrome: England and Wales 2005-2012. J Med Screen. 2014; 21(3): 113–119.
  10. Maiz N, Valencia C, Kagan KO, et al. Screening for trisomy 18 by maternal age, fetal nuchal translucency, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol. 2008; 32(4): 488–492.
  11. Kagan KO, Wright D, Valencia C, et al. Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free beta-hCG and pregnancy-associated plasma protein-A. Hum Reprod. 2008; 23(9): 1968–1975.
  12. Borenstein M, Persico N, Kagan KO, et al. Frontomaxillary facial angle in screening for trisomy 21 at 11 + 0 to 13 + 6 weeks. Ultrasound in Obstetrics and Gynecology. 2008; 32(1): 5–11.
  13. Kagan KO, Cicero S, Staboulidou I, et al. Fetal nasal bone in screening for trisomies 21, 18 and 13 and Turner syndrome at 11-13 weeks of gestation. Ultrasound Obstet Gynecol. 2009; 33(3): 259–264.
  14. Zoppi MA, Ibba RM, Axiana C, et al. Absence of fetal nasal bone and aneuploidies at first-trimester nuchal translucency screening in unselected pregnancies. Prenat Diagn. 2003; 23(6): 496–500.
  15. Cicero S, Spencer K, Avgidou K, et al. Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening. Prenat Diagn. 2005; 25(11): 977–983.
  16. Czuba B, Cnota W, Wloch A, et al. Frontomaxillary facial angle measurement in screening for trisomy 18 at 11 + 0 to 13 + 6 weeks of pregnancy: a double-centre study. Biomed Res Int. 2013; 2013: 168302.
  17. Wojda KM, Moczulska H, Sieroszewski PJ. The absence of fetal nasal bones in ultrasound examination between 11 + 0 and 13 + 6 weeks of gestation versus the occurrence of trisomies 21, 18, and 13. Ginekol Pol. 2019; 90(10): 604–606.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl